{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T04:59:17Z","timestamp":1782277157889,"version":"3.54.5"},"reference-count":15,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T00:00:00Z","timestamp":1740700800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaadcasereports.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JAAD Case Reports"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.jdcr.2025.02.005","type":"journal-article","created":{"date-parts":[[2025,3,4]],"date-time":"2025-03-04T19:34:14Z","timestamp":1741116854000},"page":"45-49","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Hidradenitis suppurativa in the setting of immune checkpoint inhibitor therapy: A case series"],"prefix":"10.1016","volume":"59","author":[{"given":"Liam M.","family":"Dalton","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara L.","family":"Fossum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Severine","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"18","key":"10.1016\/j.jdcr.2025.02.005_bib1","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1056\/NEJMra1514296","article-title":"Molecular and biochemical aspects of the PD-1 checkpoint pathway","volume":"375","author":"Boussiotis","year":"2016","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.jdcr.2025.02.005_bib2","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s11926-018-0770-0","article-title":"Immune-related adverse events in cancer patients treated with immune checkpoint inhibitors","volume":"20","author":"Sandigursky","year":"2018","journal-title":"Curr Rheumatol Rep"},{"issue":"5","key":"10.1016\/j.jdcr.2025.02.005_bib3","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/j.jaad.2019.08.090","article-title":"Hidradenitis suppurativa","volume":"82","author":"Goldburg","year":"2020","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.jdcr.2025.02.005_bib4","doi-asserted-by":"crossref","first-page":"37","DOI":"10.3390\/dermatopathology8010007","article-title":"Anti-PD-1-induced hidradenitis suppurativa","volume":"8","author":"Maillard","year":"2021","journal-title":"Dermatopathology"},{"issue":"3","key":"10.1016\/j.jdcr.2025.02.005_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaad.2022.06.716","article-title":"33911 Hidradenitis suppurativa secondary to nivolumab","volume":"87","author":"Ayoubi","year":"2022","journal-title":"J Am Acad Dermatol"},{"issue":"Supplement_1","key":"10.1016\/j.jdcr.2025.02.005_bib6","doi-asserted-by":"crossref","first-page":"i150","DOI":"10.1093\/bjd\/ljae090.315","article-title":"BI27 New-onset hidradenitis suppurativa secondary to combination therapy with programmed cell death ligand -1 inhibitor atezolizumab and vascular endothelial growth factor inhibitor bevacizumab","volume":"191","author":"Fagan","year":"2024","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jdcr.2025.02.005_bib7","author":"Kheterpal"},{"key":"10.1016\/j.jdcr.2025.02.005_bib8","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.ejca.2016.02.010","article-title":"Characterisation and management of dermatologic adverse events to agents targeting the PD-1 receptor","volume":"60","author":"Belum","year":"2016","journal-title":"Eur J Cancer"},{"issue":"16","key":"10.1016\/j.jdcr.2025.02.005_bib9","doi-asserted-by":"crossref","first-page":"4023","DOI":"10.1158\/1078-0432.CCR-15-2872","article-title":"Cytotoxic cutaneous adverse drug reactions during anti-PD-1 therapy","volume":"22","author":"Goldinger","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"3","key":"10.1016\/j.jdcr.2025.02.005_bib10","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1007\/s40257-017-0336-3","article-title":"Dermatologic reactions to immune checkpoint inhibitors: skin toxicities and immunotherapy","volume":"19","author":"Sibaud","year":"2018","journal-title":"Am J Clin Dermatol"},{"issue":"10","key":"10.1016\/j.jdcr.2025.02.005_bib11","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003066","article-title":"Immune checkpoint inhibitors in patients with pre-existing psoriasis: safety and efficacy","volume":"9","author":"Halle","year":"2021","journal-title":"J Immunother Cancer"},{"issue":"4","key":"10.1016\/j.jdcr.2025.02.005_bib12","doi-asserted-by":"crossref","first-page":"LMT51","DOI":"10.2217\/lmt-2021-0003","article-title":"Use of immune checkpoint inhibitors in patients with solid tumors and pre-existing autoimmune or inflammatory disease: real-world data","volume":"10","author":"Calvo","year":"2021","journal-title":"Lung Cancer Manag"},{"issue":"19","key":"10.1016\/j.jdcr.2025.02.005_bib13","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.139932","article-title":"Immunopathogenesis of hidradenitis suppurativa and response to anti\u2013TNF-\u03b1 therapy","volume":"5","author":"Lowe","year":"2020","journal-title":"JCI Insight"},{"key":"10.1016\/j.jdcr.2025.02.005_bib14","doi-asserted-by":"crossref","DOI":"10.3389\/bjbs.2023.11065","article-title":"Prognostic role of CD68+ and CD163+ tumour-associated macrophages and PD-L1 expression in oral squamous cell carcinoma: a meta-analysis","volume":"80","author":"Chohan","year":"2023","journal-title":"Br J Biomed Sci"},{"issue":"1","key":"10.1016\/j.jdcr.2025.02.005_bib15","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1038\/s41598-017-01661-z","article-title":"CD163+CD204+ tumor-associated macrophages contribute to T cell regulation via interleukin-10 and PD-L1 production in oral squamous cell carcinoma","volume":"7","author":"Kubota","year":"2017","journal-title":"Sci Rep"}],"container-title":["JAAD Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352512625000712?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352512625000712?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T03:20:07Z","timestamp":1775186407000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352512625000712"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":15,"alternative-id":["S2352512625000712"],"URL":"https:\/\/doi.org\/10.1016\/j.jdcr.2025.02.005","relation":{},"ISSN":["2352-5126"],"issn-type":[{"value":"2352-5126","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hidradenitis suppurativa in the setting of immune checkpoint inhibitor therapy: A case series","name":"articletitle","label":"Article Title"},{"value":"JAAD Case Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jdcr.2025.02.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc. on behalf of the American Academy of Dermatology, Inc.","name":"copyright","label":"Copyright"}]}}